{"id":"bisoprolol-versus-nebivolol","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Fatigue"},{"rate":"3-8%","effect":"Dizziness"},{"rate":"2-5%","effect":"Bradycardia"},{"rate":"2-5%","effect":"Hypotension"},{"rate":"2-4%","effect":"Headache"},{"rate":"1-3%","effect":"Dyspnea"}]},"_chembl":{"chemblId":"CHEMBL434394","moleculeType":"Small molecule","molecularWeight":"405.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bisoprolol and nebivolol are cardioselective beta-blockers that preferentially inhibit beta-1 adrenergic receptors on cardiac tissue, decreasing heart contractility and heart rate. Nebivolol has additional vasodilatory properties mediated through nitric oxide release, which may provide additional cardiovascular benefits beyond standard beta-blockade. Both agents are used to manage hypertension and heart failure by reducing cardiac workload and improving diastolic function.","oneSentence":"Both bisoprolol and nebivolol are beta-1 selective adrenergic receptor antagonists that reduce heart rate and blood pressure by blocking sympathetic nervous system signaling in the heart.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:15.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Angina pectoris"},{"name":"Post-myocardial infarction management"}]},"trialDetails":[{"nctId":"NCT04432610","phase":"PHASE4","title":"Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects","status":"WITHDRAWN","sponsor":"Clinical Hospital Center Zemun","startDate":"2030-01","conditions":"Bisoprolol Adverse Reaction, Nebivolol Adverse Reaction","enrollment":""},{"nctId":"NCT00878384","phase":"NA","title":"Catheter Ablation Versus Medical Rate Control for Atrial Fibrillation in Patients With Heart Failure","status":"COMPLETED","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2009-04","conditions":"Atrial Fibrillation, Heart Failure","enrollment":52},{"nctId":"NCT00517725","phase":"PHASE4","title":"Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure","status":"COMPLETED","sponsor":"Centro Cardiologico Monzino","startDate":"2007-07","conditions":"Chronic Heart Failure","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Bisoprolol versus Nebivolol","genericName":"Bisoprolol versus Nebivolol","companyName":"Clinical Hospital Center Zemun","companyId":"clinical-hospital-center-zemun","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Both bisoprolol and nebivolol are beta-1 selective adrenergic receptor antagonists that reduce heart rate and blood pressure by blocking sympathetic nervous system signaling in the heart. Used for Hypertension, Heart failure with reduced ejection fraction, Angina pectoris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}